Forxiga HF General Drug Use-Results Study

AstraZeneca

Status: Completed

Conditions: Heart Failure

Study type: Observational

Funder types: Industry

Identifiers

NCT04865406

D1699C00017

Details and patient eligibility

About

To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.

Full description

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch.

1. ADRs which are unexpected from the precautions for use
2. Understanding of incidence of ADRs during use of Forxiga in the real world setting
3. Factors possibly having an impact on the safety

Enrollment: 1,221 patients

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged more than 15 years
• Patients who have been prescribed Forxiga for the first time

Exclusion criteria

• Patients with a history of hypersensitivity to any ingredients of this drug.
• Patients with severe ketosis, diabetic coma or precoma
• Patients with severe infections, before or after a surgery, or with serious trauma